About Vernalis plc (LON:VER)
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Trailing EPSGBX (0.04)
Return on Equity-23.94%
Return on Assets-20.89%
Frequently Asked Questions for Vernalis plc (LON:VER)
What is Vernalis plc's stock symbol?
Vernalis plc trades on the London Stock Exchange (LON) under the ticker symbol "VER."
How were Vernalis plc's earnings last quarter?
Vernalis plc (LON:VER) announced its quarterly earnings results on Tuesday, September, 12th. The company reported ($4.10) earnings per share for the quarter, topping analysts' consensus estimates of ($4.50) by $0.40. The business had revenue of $20.79 million for the quarter. Vernalis plc had a negative return on equity of 23.94% and a negative net margin of 69.02%. View Vernalis plc's Earnings History.
Where is Vernalis plc's stock going? Where will Vernalis plc's stock price be in 2017?
6 analysts have issued 1 year price objectives for Vernalis plc's stock. Their predictions range from GBX 21 to GBX 88. On average, they expect Vernalis plc's share price to reach GBX 39.40 in the next year. View Analyst Ratings for Vernalis plc.
Who are some of Vernalis plc's key competitors?
Some companies that are related to Vernalis plc include Asterias Biotherapeutics (AST), Compugen (CGEN), Advaxis (ADXS), Matinas BioPharma Holdings (MTNB), Oramed Pharmaceuticals (ORMP), CTI BioPharma Corp. (CTIC), ArQule (ARQL), aTyr Pharma (LIFE), Eiger BioPharmaceuticals (EIGR), BioLineRx (BLRX), Infinity Pharmaceuticals (INFI), Sunesis Pharmaceuticals (SNSS), Galectin Therapeutics (GALT), Regulus Therapeutics (RGLS), Senomyx (SNMX), Novelion Therapeutics (NVLN), Brainstorm Cell Therapeutics (BCLI) and NovaBay Pharmaceuticals (NBY).
Who are Vernalis plc's key executives?
Vernalis plc's management team includes the folowing people:
- Ian R. Garland, Chief Executive Officer, Executive Director (Age 48)
- David Mackney, Chief Financial Officer, Executive Director (Age 46)
- Kevin Kissane, Company Secretary (Age 58)
- Peter J. Fellner, Non-Executive Chairman of the Board (Age 73)
- Ian David Gilham Ph.D., Non-Executive Director (Age 56)
- Lisa Amster Schoenberg, Non-Executive Director (Age 48)
- Carol C. Ferguson, Senior Independent Non-Executive Director (Age 69)
- Nigel Sheail, Non-Executive Independent Director (Age 48)
How do I buy Vernalis plc stock?
Shares of Vernalis plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Vernalis plc's stock price today?
One share of Vernalis plc stock can currently be purchased for approximately GBX 12.75.
How big of a company is Vernalis plc?
Vernalis plc has a market capitalization of £67.78 million.
How can I contact Vernalis plc?
Vernalis plc's mailing address is 100 Berkshire Place, Wharfedale Road, WOKINGHAM, RG41 5RD, United Kingdom. The company can be reached via phone at +44-118-9380000.
MarketBeat Community Rating for Vernalis plc (VER)MarketBeat's community ratings are surveys of what our community members think about Vernalis plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History and Estimates Chart for Vernalis plc (LON:VER)
Earnings History by Quarter for Vernalis plc (LON VER)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/12/2017||Y 2017||GBX (4.50)||GBX (4.10)||GBX 2,079 million||View||N/A|
Earnings Estimates for Vernalis plc (LON:VER)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Vernalis plc (LON:VER)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vernalis plc (LON VER)
Insider Trades by Quarter for Vernalis plc (LON VER)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/12/2016||David Mackney||Insider||Sell||27,233||GBX 39||£10,620.87|
|9/30/2016||Carol Ferguson||Insider||Buy||28,000||GBX 41||£11,480|
|5/5/2015||Nigel Sheail||Insider||Buy||84,000||GBX 59.90||£50,316|
Latest Headlines for Vernalis plc (LON VER)
Financials are not available for this stock.
Vernalis plc (LON VER) Chart for Friday, November, 24, 2017